Loading
Breast Cancer Treatment Studies / Multiple and Secondary Primary Cancers · Journal article
World Journal of Advanced Research and Reviews · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case of triple-negative breast cancer with synchronous visceral and CNS metastases, characterized by aggressive biological features (grade 3, Ki-67 78%, TP53 and PIK3CA mutations) and rapid progression despite multimodal therapy, culminating in death seven months after diagnosis. The report documents the clinical and pathological phenotype of de novo metastatic TNBC but provides no comparative efficacy data or outcome generalizable beyond this patient.
Case report. A 52-year-old woman with untreated left breast mass presenting with progressive headache, visual disturbance, back pain, and exertional dyspnea.. Intervention: Stereotactic radiosurgery to brain metastases, palliative radiation to vertebral lesions, systemic chemoimmunotherapy, and bone-modifying therapy..
52-year-old woman with 4.8-cm left breast lesion and synchronous three brain metastases, bilateral pulmonary nodules, and multifocal osseous metastases Tumor ER-negative, PR-negative, HER2-negative (IHC score 0, non-amplified); Ki-67 proliferation index 78% TP53 and PIK3CA mutations detected; focal cytokeratin 5/6 and EGFR expression
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case underscores the aggressive biology and rapid CNS dissemination characteristic of TNBC and supports the need for prompt neurologic assessment, multidisciplinary care, and early biomarker-driven treatment discussion in metastatic TNBC. However, no therapeutic recommendations can be drawn from a single case; outcomes reflect this patient's disease trajectory and treatment response, not generalizable efficacy.
A single case report with detailed pathological and clinical description; illustrative of aggressive TNBC phenotype and CNS dissemination pattern, but no comparative data, outcome measure, or generalizable evidence.
As stated by the source record.
Quoted from the source exactly as published.
This case underscores the aggressive biology and rapid CNS dissemination characteristic of TNBC and supports the need for prompt neurologic assessment, multidisciplinary care, and early biomarker-driven treatment discussion in metastatic TNBC. However, no therapeutic recommendations can be drawn from a single case; outcomes reflect this patient's disease trajectory and treatment response, not generalizable efficacy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Triple-negative breast cancer (TNBC) is an aggressive immunophenotypic category lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, with a particular propensity for early visceral and central nervous system dissemination. We report a 52-year-old woman with an untreated left breast mass, progressive headache and visual disturbance, back pain, and exertional dyspnea. Staging demonstrated a 4.8-cm left breast lesion with axillary adenopathy, three brain metastases, bilateral pulmonary nodules, and multifocal osseous metastases. Core biopsies of the breast and lung showed concordant grade 3 invasive breast carcinoma of no special type with extensive high-grade ductal carcinoma in situ. The tumor was ER-negative, PR-negative, and HER2-negative (IHC score 0, non-amplified), GATA3-positive, and TTF-1/Napsin A-negative. The tumor cells showed high proliferation (Ki-67, 78%); focal cytokeratin 5/6 and EGFR expression, together with TP53 and PIK3CA mutations, supported a biologically aggressive TNBC. Symptomatic cerebral lesions were treated with stereotactic radiosurgery, painful vertebral disease with palliative radiation, and systemic chemoimmunotherapy plus bone-modifying therapy produced an initial response. However, new brain metastases, progressive skeletal disease with pathologic L2 fracture, and leptomeningeal dissemination developed rapidly. She died seven months after diagnosis. This case highlights the need for urgent neurologic assessment, tissue-confirmed staging, assay-specific biomarker interpretation, and early multidisciplinary and supportive care in de novo metastatic TNBC with CNS involvement.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.